MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
2.060
+0.090
+4.57%
After Hours: 2.060 0 0.00% 18:10 05/22 EDT
OPEN
1.970
PREV CLOSE
1.970
HIGH
2.100
LOW
1.950
VOLUME
841.43K
TURNOVER
--
52 WEEK HIGH
7.85
52 WEEK LOW
1.285
MARKET CAP
226.01M
P/E (TTM)
-1.7862
1D
5D
1M
3M
1Y
5Y
1D
Annexon presents tanruprubart data at PNS annual meeting
TipRanks · 3d ago
Annexon, Inc. Presents Positive Real-World Evidence for Tanruprubart in Guillain-Barré Syndrome at 2025 PNS Annual Meeting
NASDAQ · 3d ago
Annexon Presents Data Highlighting Outcomes With Tanruprubart At 2025 Peripheral Nerve Society Annual Meeting
Benzinga · 3d ago
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
Barchart · 3d ago
Buy Rating on Annexon Biosciences: Promising ANX005 for GBS and Strategic Path to FDA Approval
TipRanks · 3d ago
Weekly Report: what happened at ANNX last week (0512-0516)?
Weekly Report · 4d ago
ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 05/14 12:01
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.